Viking Therapeutics jumps after experimental drug shows durable weight-loss benefit
VKTX•Shares rise after VK2735 study results
** Shares of Viking Therapeutics VKTX.O rise 41.2% to $42.32 premarket
** Weight-loss drug developer says patients who switched to every-other-week dosing of experimental drug VK2735 maintained up to 97% of the weight they had lost during an initial 21-week treatment period in a study
** Those moved to monthly dosing retained up to 90% of their prior weight loss over the following 12 weeks
** Up to last close, stock down 14.4% YTD
